Healthcare
PetVivo Holdings, Inc.(PETV)
Live Price
Offline$0.78
-8.24% today
1Y Change
-2.50%
Window
Jun 23, 2025 โ Jun 17, 2026
- Market Cap
- $20.00M
- Revenue Growth
- +16.9%
- EPS Growth
- +47.4%
- Dividend Yield
- 0.0%
Coverage: 248 bars ยท Jun 23, 2025 โ Jun 17, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
PetVivo Holdings, Inc. (PETV) is a Healthcare stock with a market cap of $20.00M and listed on OTC. The stock last traded around $0.78 and down 2.5% across the available one-year price window (Jun 23, 2025 โ Jun 17, 2026). Baseline metrics include revenue growth of +16.9%, EPS growth of +47.4%, a dividend yield of 0.0%. What stands out right now is revenue +16.9%, EPS +47.4%, free cash flow +23.9% with operating margin -735.9% and ROIC -237.2%. Valuation already assumes a fairly strong business story at price/sales 19.0. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines PETV price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Above sector median
+16.9% vs +7.6% peer median
Operating Margin
Below sector median
-735.9% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on Feb 17, 2026, but the surprise data is still limited.
The operating story is still moving forward
Revenue is running at +16.9% and EPS at +47.4%, with operating margin around -735.9%.
The next real check-in already has a date
The next earnings event is scheduled for Jun 25, 2026, which is the clearest near-term catalyst for confirming whether the current trend is holding up.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -2.7% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 Feb 17, 2026 | โ | +4.0% | +4.5% | +13.6% |
2025 Nov 14, 2025 | โ | -9.8% | -18.8% | -10.5% |
2025 Aug 14, 2025 | โ | +3.4% | +6.3% | +14.8% |
Benchmark Comparison
Normalized Performance vs SPY
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PETV
โ
Normalized return
SPY
โ
S&P 500
Excess Return
โ
Relative to SPY
PETV Max Drawdown
-56.00%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for PETV and SPY.
Company Overview
PetVivo Holdings, Inc.
Other OTC
PetVivo Holdings, Inc., a biomedical device company, engages in the manufacturing, commercializing, and licensing of medical devices and biomaterials for the treatment of afflictions and diseases in animals. Its lead product is Spryng, a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The company's pipeline products also include 17 therapeutic devices for veterinary and human clinical applications. PetVivo Holdings, Inc. was founded in 2009 and is headquartered in Minneapolis, Minnesota.
- Leadership
- John Lai
- IPO Date
- Sep 8, 2014
- Employees
- 20
- Street Address
- 5251 Edina Industrial Boulevard
- Mailing
- Minneapolis, MN, 55439
- Region
- Minneapolis, MN, US
- Reporting Currency
- USD
- Investor Line
- 952 405 6216
- Last Updated
- May 3, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- โ
- Price/Sales
- 19.0
- Price/Book
- 7.8
Growth
- Revenue
- +16.9%
- EPS
- +47.4%
- Free Cash Flow
- +23.9%
Profitability
- Gross Margin
- 66.0%
- Operating Margin
- -735.9%
- Net Margin
- -893.3%
- ROE
- -256.1%
- ROIC
- -237.2%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 1.40
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.